Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial

BMC Psychiatry

Barbara Schäuble⁴  Michel van Agthoven²  Annemarie van der Kolk²  Joachim Dejonckheere⁷  Sandra Wächter⁶  Alexandra Philipsen¹  Michael Rösler³  J J Sandra Kooij⁵ 

[1] Department of Psychiatry, University Hospital, Hugstetter Strasse 49, D-79095, Freiburg, Germany;Janssen–Cilag B.V, Dr. Paul Janssenweg 150, 5026 RH, Tilburg, The Netherlands;Saarland University Hospital, Neurocentre, Bdg 90.3, D-66421, Homburg/Saar, Germany;Formerly Janssen Medical Affairs Europe, Middle East & Africa; now at UCB Pharma S.A, Allée de la Recherche, 60, 1070, Brussels, Belgium;Psycho-Medical Programs, PsyQ, Program Adult ADHD, Carel Reinierszkade 197, 2593, HR Den Haag, The Netherlands;Janssen Medical Affairs Europe, Middle East & Africa, Johnson & Johnson Platz 5a, D-41470, Neuss, Germany;SGS Life Science Services, Generaal de Wittelaan 19 A bus 5, 2800, Mechelen, Belgium

关键词: OROS methylphenidate;    Non-adherence;    Compliance;    Efficacy;    CAARS:O-SV;    ADHD;    Adults;    Adherence;   

Others  :  1124157
DOI  :  10.1186/1471-244X-13-36

 received in 2012-03-30, accepted in 2013-01-02,  发布年份 2013

【 摘 要 】

Background

Medication non-adherence has an important impact on treatment efficacy and healthcare burden across a range of conditions and therapeutic areas. The aim of this analysis was to determine predictors of non-adherence and impact of non-adherence on treatment response in adults with attention-deficit/hyperactivity disorder (ADHD).

Methods

Post-hoc analysis of a 13-week randomized, double-blind placebo-controlled study of OROS methylphenidate (MPH) 54 and 72 mg/day. Primary efficacy variable was the Conners’ Adult ADHD Rating Scale – Screening Version (CAARS:O-SV). Daily adherence was calculated as average daily adherence (100 × capsules taken/2), with overall adherence calculated as the average daily adherence. Predictors of adherence were assessed using mixed-effects logistic regression. Descriptive statistics were generated for change in CAARS:O-SV score for adherent (> 95% adherence) and non-adherent subjects. Predictors of change were analyzed using a mixed model.

Results

Subjects were allocated to OROS MPH (54 mg, n = 87; 72 mg, n = 92) or placebo (n = 97). Mean adherence was 92.6% and 93.3% (OROS MPH 54 and 72 mg/day, respectively), versus 97.5% (placebo). Adherence was higher and less variable in completers. Factors significantly associated with non-adherence included female sex, shorter time since ADHD diagnosis, higher education level (completion of university) and score on the Drug Use Screening Inventory psychiatric disorders subscale. Improvements from baseline in CAARS:O-SV score were numerically greater in subjects defined as adherent than in those who were non-adherent. Significant predictors of CAARS:O-SV change in patients who completed the study included percentage adherence up to the point of assessment (p < 0.0001), baseline score (p < 0.0001) and family history of ADHD (p = 0.0003).

Conclusion

The results of this analysis suggest that newly diagnosed patients, those with a high score on the DUSI-R psychiatric disorder scale, women, and subjects with high educational degrees may be at increased risk of non-adherence. Clinicians and policymakers should therefore pay special attention to these individuals, as non-adherence is a significant predictor of reduced response to treatment.

Trial registration

EudraCT #: 2007-002111-82

【 授权许可】

   
2013 Kooij et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Bubalo J, Clark RK Jr, Jiing SS, Johnson NB, Miller KA, Clemens-Shipman CJ, Sweet AL: Medication adherence: pharmacist perspective. J Am Pharm Assoc 2010, 50:394-406.
• [2]Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008, 2:CD000011.
• [3]Julius RJ, Novitsky MA Jr, Dubin WR: Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 2009, 15:34-44.
• [4]Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
• [5]Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC: Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009, 15:e22-e33.
• [6]Adler LD, Nierenberg AA: Review of medication adherence in children and adults with ADHD. Postgrad Med 2010, 122:184-191.
• [7]Darredeau C, Barrett SP, Jardin B, Pihl RO: Patterns and predictors of medication compliance, diversion, and misuse in adult prescribed methylphenidate users. Hum Psychopharmacol 2007, 22:529-556.
• [8]Safren SA, Duran P, Yovel I, Perlman CA, Sprich S: Medication adherence in psychopharmacologically treated adults with ADHD. J Atten Disord 2007, 10:257-260.
• [9]CADDRA: Canadian ADHD Practice Guidelines. Toronto: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance; 2008.
• [10]Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P: European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010, 10:67. BioMed Central Full Text
• [11]National Collaborating Centre for Mental Health: Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. London: National Institute for Health and Clinical Excellence; 2009.
• [12]National Steering Committee on Multidisciplinary Guideline Development: Multidisciplinary Guideline on ADHD [in Dutch]. Utrecht: Trimbos Institute; 2005.
• [13]Sosial- og helsedirektoratet: Diagnosis and Treatment of Hyperkinetic Disorder/Attention Deficit Hyperactivity Disorder (ADHD) in Children, Adolescents and Adults [in Norwegian]. Oslo: Sosial- og helsedirektoratet; 2010.
• [14]Johnston C, Pelham WE, Hoza J, Sturges J: Psychostimulant rebound in attention deficit disordered boys. J Am Acad Child Adolesc Psychiatry 1988, 27:806-810.
• [15]Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK: Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder: a randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004, 34:973-982.
• [16]Janssen–Cilag Ltd: Concerta XL 18 mg–36 mg Prolonged Release Tablets. High Wycombe: Janssen–Cilag Ltd; 2010.
• [17]Medori R, Ramos-Quiroga JA, Casas M, Kooij JJS, Niemelä A, Trott GE, Lee E, Buitelaar JK: A randomized, placebo-controlled trial of 3 fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008, 63:981-989.
• [18]Casas M, Rösler M, Kooij JJS, Ginsberg Y, Ramos-Quiroga JA, Heger S, Berwaerts J, Dejonckheere J, van der Vorst E, Schäuble B: Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J Biol Psychiatry 2011. Epub ahead of print
• [19]Conners C, Erhardt D, Sparrow E: Conners’ Adult ADHD Rating Scales (CAARS): Technical Manual. North Tonawanda: Multi-Health Systems; 1999.
• [20]Christiansen H, Kis B, Hirsch O, Matthies S, Hebebrand J, Uekermann J, Abdel-Hamid M, Kraemer M, Wiltfang J, Graf E, Colla M, Sobanski E, Alm B, Rösler M, Jacob C, Jans T, Huss M, Schimmelmann BG, Philipsen A: German validation of the Conners Adult ADHD Rating Scales (CAARS) II: Reliability, validity, diagnostic sensitivity and specificity. Eur Psychiatry 2012, 27:321-328.
• [21]Tarter R, Hegedus A: The Drug Use Screening Inventory: its application in the evaluation and treatment of alcohol and drug abuse. Alcohol Health Res World 1991, 15:65-75.
• [22]Goldstein H: Multilevel Statistical Models. London: Institute of Education, Multilevel Models Project; 1999.
• [23]Steiner JF: Can we identify clinical predictors of medication adherence… and should we? Med Care 2010, 48:193-195.
• [24]Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW, Ereshefsky L, Miller AL: Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007, 58:1187-1192.